Core Insights - Exelixis reported a revenue of $555.45 million for the quarter ended March 2025, marking a 30.6% increase year-over-year and exceeding the Zacks Consensus Estimate by 10.44% [1] - The company's EPS for the quarter was $0.62, significantly up from $0.17 in the same quarter last year, resulting in an EPS surprise of 47.62% compared to the consensus estimate of $0.42 [1] Revenue Breakdown - Net product revenues reached $513.28 million, surpassing the average estimate of $448.24 million by nine analysts, reflecting a year-over-year increase of 35.6% [4] - CABOMETYX generated $510.87 million in net product revenues, exceeding the estimated $433.73 million by seven analysts, with a year-over-year growth of 35.7% [4] - COMETRIQ's net product revenues were $2.41 million, compared to the estimated $3.39 million, showing a year-over-year increase of 14.5% [4] - License revenues totaled $42.48 million, falling short of the average estimate of $44.61 million, representing a year-over-year decline of 4.9% [4] - Collaboration services reported a loss of $0.32 million, significantly below the average estimate of $2.43 million, indicating a drastic year-over-year change of -115.6% [4] Stock Performance - Over the past month, Exelixis shares have returned +3.5%, while the Zacks S&P 500 composite has increased by +9.1%, suggesting underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it may perform in line with the market in the near term [3]
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates